Alchemab was delighted to see this article in Alzforum highlighting Alchemab’s unique platform and preclinical Alzheimers candidate ATLX-1088 targeting CD33. This article explores data that Ralph Minter, our Senior Vice President of Research, presented at AD/PD –Advances in Science & Therapy 2024 International Conference on Alzheimer’s and Parkinson’s Diseases. Read More

Alchemab’s Donna Finch, Head of Translational and Clinical Science, presented data on a potential first-in-class disease modifying therapeutic for Huntington’s Disease at the annual CHDI Huntington’s Disease Therapeutics Conference in Dubrovnik, Croatia, on the 26 April 2023. Our innovative, target agnostic discovery platform, which combines data analysis of hundreds of millions of individual antibodies with […]